Does Blue Cross Blue Shield Cover Weight Loss Medications? The 2026 Plan-by-Plan Answer

Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Blue Cross Blue Shield coverage for GLP-1 weight loss medications depends on three variables: plan type (commercial vs Medicare Advantage vs Federal Employee), state, and employer group decisions
• For 2026, the FEP Blue formulary lists Wegovy and Saxenda at Tier 3 on Standard and Basic Option (not covered on FEP Blue Focus) with prior authorization under policy 5.99.027; Zepbound is non-formulary and available only by exception under policy 5.99.031, and compounded GLP-1s are not covered
• Employer coverage is the employer's choice: in a 2026 survey of 307 employers reported by healthinsurance.org, 36 percent covered GLP-1s for weight loss and 60 percent for diabetes, and plans that cover them require prior authorization with a BMI threshold of 30 (or 27 with a comorbidity)
• Medicare Part D still excludes weight-loss drugs by statute, but since July 1, 2026 the Medicare GLP-1 Bridge prices Wegovy, the Zepbound KwikPen and Foundayo at $50 a month for eligible beneficiaries through December 31, 2027; Ozempic and Mounjaro remain covered for diabetes

The short answer

Blue Cross Blue Shield coverage for weight loss medications varies by plan. Federal Employee Program Standard and Basic Option cover Wegovy (Tier 3) with prior authorization, and Zepbound only by formulary exception. Commercial employer plans cover FDA-approved obesity drugs when the employer includes that benefit, which 36 percent of employers did in a 2026 survey. Medicare Advantage drug coverage follows Part D, which excludes weight-loss drugs, but the Medicare GLP-1 Bridge now covers Wegovy and the Zepbound KwikPen for $50 a month.

Table of contents

1. The three-variable coverage formula
2. Federal Employee Program (FEP) coverage: the 2026 update
3. Commercial employer-sponsored plans: when your boss decides
4. Medicare Advantage BCBS plans: the federal prohibition
5. State-specific variations that override national policy
6. The prior authorization maze: what BCBS actually requires
7. Covered vs non-covered medications: the FDA approval line
8. What most articles get wrong about "medical necessity"
9. The compounded medication question
10. How to verify your specific plan in under 10 minutes
11. The appeal process when you get denied
12. FEP Blue 2026 by option
13. BCBS Massachusetts and Michigan policies
14. Wegovy PA checklist
15. Medicare GLP-1 Bridge: $50 a month
16. Diabetes version vs weight-loss version
17. FAQ
18. Sources

The three-variable coverage formula

Blue Cross Blue Shield is not a single insurance company. It's a federation of 34 independent companies operating under a shared brand. A BCBS plan in Illinois is a different legal entity than a BCBS plan in Texas, and they make independent coverage decisions.

Three variables determine whether your specific BCBS plan covers weight loss medications:

Variable 1: Plan type.

• Federal Employee Program (FEP)
• Commercial employer-sponsored
• Individual/family marketplace
• Medicare Advantage
• Medicaid (in states where BCBS administers Medicaid)

Variable 2: State. BCBS of Massachusetts operates under different state insurance regulations than BCBS of Alabama. Some states mandate obesity treatment coverage; most do not.

Variable 3: Employer group decision (for commercial plans). Employers purchase a base plan and then opt in or out of specific riders. Obesity medication coverage is almost always an optional rider, not part of the base plan. Your employer decides whether to pay for that rider.

This three-variable structure is why "Does BCBS cover Wegovy?" has no single answer. The question requires three follow-up questions before it's answerable.

Federal Employee Program (FEP) coverage: the 2026 update

The Federal Employee Program is the largest single BCBS plan. FEP operates under the Office of Personnel Management (OPM) and publishes one formulary and one set of pharmacy policies a year, which makes it the easiest BCBS plan to check. The table below was corrected in September 2026 against the 2026 formulary book.

As of January 1, 2026, FEP covers:

Medication	Brand name	Coverage status	Prior auth required	Tier
Semaglutide 2.4 mg	Wegovy	Covered on Standard and Basic Option; not covered on FEP Blue Focus	Yes (policy 5.99.027)	Tier 3
Tirzepatide (obesity indication)	Zepbound	Non-formulary; formulary exception only	Yes (policy 5.99.031, two oral drug trials)	Not on the 2026 formulary
Liraglutide 3.0 mg	Saxenda	Covered on Standard and Basic Option; not covered on FEP Blue Focus	Yes (policy 5.99.027)	Tier 3
Naltrexone/bupropion	Contrave	Not named among FEP's covered alternatives to Zepbound; check the formulary book	See formulary	See formulary
Phentermine/topiramate	Qsymia	Named as a covered alternative to Zepbound	See formulary	See formulary

The current rules come from FEP pharmacy policy 5.99.027 (weight-loss medications) and policy 5.99.031 (Zepbound), both effective January 1, 2026. The 5.99.027 policy history notes that in December 2024 FEP placed Saxenda, Wegovy and Zepbound on their own policies and added a behavior-modification requirement.

Prior authorization requirements for FEP GLP-1 coverage:

• Age 18 or older with BMI 30 or higher, or BMI 27 or higher with established cardiovascular disease or a weight-related comorbidity (type 2 diabetes, dyslipidemia, hypertension); ages 12 to 17 at or above the 95th BMI percentile. A Zepbound exception under policy 5.99.031 additionally requires a trial of two oral weight-management medications
• Participation in a comprehensive weight-management program (policy 5.99.027 names Teladoc as an example)
• No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Initial approval 6 months; renewal for 12 months requires at least 5 percent loss of baseline weight, or maintenance of that loss; no concurrent GLP-1 therapy

FEP does not cover compounded semaglutide or tirzepatide; neither appears on the 2026 formulary.

What Tier 3 costs depends on the option; check the 2026 FEP brochure for the Tier 3 cost share on Standard and Basic Option. Ozempic and Mounjaro, by contrast, are Tier 2 on all three options for diabetes.

Commercial employer-sponsored plans: when your boss decides

Commercial BCBS plans (the kind most working adults have) treat obesity medication coverage as an optional benefit that employers purchase separately from the base medical plan.

In a 2026 survey of 307 U.S. employers reported by healthinsurance.org (updated August 20, 2026), 36 percent covered GLP-1s for weight loss, unchanged from 2025, and 60 percent covered them for diabetes; 5 to 10 percent of employers that cover weight loss said they plan to drop it in 2027. Coverage is still the minority position.

The employer decision calculus: Employers balance three factors when deciding whether to add obesity medication coverage:

1. Premium cost increase. Adding GLP-1 coverage raises the plan's drug spend, and consultants model that as a per-employee premium increase that depends on the workforce's obesity prevalence and the plan's cost-sharing design.

1. Utilization projections. The plan models how many covered employees are eligible and how many will fill; at a list price of $1,349.02 a month for Wegovy before rebates, even a few percent of a large workforce is millions of dollars a year.

1. Long-term health cost offset. Employers expect obesity treatment to reduce downstream costs (diabetes, cardiovascular events, joint replacement). The offset takes 5 to 7 years to materialize, which matters for companies with high employee turnover.

Employers in industries with low turnover (utilities, government contractors, higher education) are more likely to add coverage. Employers in high-turnover industries (retail, hospitality, logistics) are less likely.

When your employer does offer coverage, expect these restrictions:

Restriction type	How common	Typical requirement
BMI threshold	Nearly universal	BMI ≥30, or ≥27 with comorbidity
Step therapy	Some plans (FEP requires two oral drugs before a Zepbound exception)	Must fail phentermine or Contrave first
Lifestyle program requirement	Common (FEP and BCBS Michigan both require it)	12 to 16 weeks documented diet/exercise
Quantity limits	Common (FEP: 6-month initial approval, 5 percent loss to renew)	1-year trial, must show 5% weight loss to continue
Prescriber restrictions	Less common	Must be endocrinologist or bariatric specialist

The step therapy requirement is the most common denial reason. Plans require patients to try older, cheaper medications (phentermine, Contrave, Qsymia) and document failure before approving a GLP-1. "Failure" is defined as either intolerable side effects or less than 5% weight loss after 12 weeks at therapeutic dose.

Medicare Advantage BCBS plans: the federal prohibition

Medicare Advantage plans, including those administered by BCBS, operate under federal Medicare rules. The Social Security Act explicitly excludes coverage for "drugs used for weight loss" under Medicare Part D.

This prohibition has been in place since the Medicare Modernization Act of 2003 and remains in the statute as of 2026. What changed is administrative: from July 1, 2026 through December 31, 2027, the CMS Innovation Center's Medicare GLP-1 Bridge pays for Wegovy (pen and pill), the Zepbound KwikPen and Foundayo outside the Part D benefit for a $50 monthly copay, with prior authorization through a single central processor. See the Bridge section below.

The diabetes loophole: Medicare Advantage plans cover GLP-1 medications when prescribed for FDA-approved diabetes indications:

• Semaglutide (Ozempic) for type 2 diabetes
• Tirzepatide (Mounjaro) for type 2 diabetes
• Liraglutide (Victoza) for type 2 diabetes
• Dulaglutide (Trulicity) for type 2 diabetes

These are the same active ingredients as Wegovy (semaglutide) and Zepbound (tirzepatide), but at different doses and with different FDA indications.

Some physicians prescribe Ozempic or Mounjaro off-label for weight loss in Medicare patients. This is legal prescribing, and Medicare Advantage plans will cover it if the claim is submitted with a diabetes diagnosis code. However, this requires the patient to have a documented diabetes diagnosis (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL on two occasions).

Prescribing diabetes medications to non-diabetic patients solely for weight loss and using a diabetes diagnosis code is insurance fraud. Some physicians do it anyway. The risk falls on both the prescriber and the patient.

What about Medicaid BCBS plans? Medicaid coverage rules vary by state. As of 2025, 16 states covered GLP-1 medications for weight loss under Medicaid; four of them (California, New Hampshire, Pennsylvania and South Carolina) ended that coverage in 2026, and Michigan now requires a BMI of at least 40, according to healthinsurance.org. BCBS administers Medicaid in several states (Illinois, New Mexico, Texas, among others), and coverage follows state Medicaid policy, not BCBS commercial policy.

State-specific variations that override national policy

State law shapes coverage through two channels: the essential-health-benefit benchmark each state sets for individual and small-group plans, and any mandate a legislature passes. The table below replaces an earlier version whose dates could not be verified; it lists what can be checked as of September 2026.

State	Law effective date	Coverage requirement	Exclusions
North Dakota	2025 plan year	Only state whose essential-health-benefit benchmark plan specifically includes GLP-1 coverage for weight loss (morbid obesity)	Applies to individual and small-group plans, not self-funded employer plans (healthinsurance.org)
Most other states	Benchmarks not updated since the 2017 plan year	No GLP-1 weight-loss requirement	Marketplace plans rarely cover them: 26 of about 300 carriers in a 2026 analysis, most limited to BMI 40 or higher (healthinsurance.org)
Massachusetts	January 1, 2026 on renewal	BCBS Massachusetts excluded Wegovy, Saxenda and Zepbound from standard coverage; groups over 100 employees can buy it back	Benefit exclusion, so it cannot be appealed (BCBSMA FAQ, May 1, 2025)
Michigan	September 2026 guideline	BCBS Michigan covers Wegovy and Zepbound where the group benefit includes them, with published criteria	Medicaid now requires BMI 40 or higher for weight-loss GLP-1s (healthinsurance.org)

The ERISA exemption is important. Self-funded employer plans (where the employer pays claims directly and hires BCBS only to administer the plan) are governed by federal ERISA law, which preempts state insurance mandates. About 64% of employees with employer-sponsored insurance are in self-funded plans.

If you work for a large employer, your plan is probably self-funded and therefore not subject to your state's benchmark or mandate rules.

State mandates apply only to fully insured plans (where the employer pays a premium to BCBS and BCBS assumes the financial risk). Fully insured plans are more common among small employers (under 200 employees).

The pattern that decides approvals: whether the plan covers the category at all, and whether the submission answers every written criterion. In practice that sorts into four groups:

• FEP plans: approved when the 5.99.027 criteria are documented; Zepbound only by exception
• Commercial plans where the employer bought the benefit: approved when the criteria are documented
• Commercial plans that exclude the category: denied regardless of documentation (BCBS Massachusetts calls its 2026 exclusion non-appealable)
• Medicare Advantage: diabetes indication only under Part D, plus the $50 GLP-1 Bridge for obesity since July 1, 2026

That is why an overall BCBS approval rate would be meaningless: it would mix plans that cover the drugs with plans that exclude them.

The prior authorization maze: what BCBS actually requires

Prior authorization (PA) is the process where your doctor requests approval from BCBS before the pharmacy will fill the prescription. For GLP-1 weight loss medications, PA is required on 100% of BCBS plans that cover them.

Standard BCBS prior authorization criteria (commercial plans that cover obesity medications):

1. Diagnosis code: ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified)

1. BMI documentation: Current BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one of:

• Hypertension (on medication)
• Type 2 diabetes or prediabetes (HbA1c 5.7% to 6.4%)
• Dyslipidemia (on medication)
• Obstructive sleep apnea (documented with sleep study)
• Cardiovascular disease

1. Lifestyle modification documentation: Letter from prescriber documenting patient participation in a structured weight management program for at least 12 weeks, including:

• Dietary counseling or supervised diet plan
• Physical activity plan
• Documentation of adherence (food logs, activity logs, or attendance records)

1. Step therapy (some plans; FEP requires two oral drugs before a Zepbound exception): Documentation that patient tried and failed one of:

• Phentermine (at least 12 weeks at therapeutic dose)
• Phentermine/topiramate (Qsymia, at least 12 weeks)
• Naltrexone/bupropion (Contrave, at least 12 weeks)

"Failed" means either intolerable side effects documented in medical record, or less than 5% total body weight loss after 12 weeks.

1. Contraindication screening: Documentation that patient does not have:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis (some plans)
• Pregnancy or planning pregnancy

1. Prescriber qualification: Prescription must come from MD, DO, NP, or PA. Some plans require endocrinology or obesity medicine specialty.

The 72-hour to 14-day approval window: BCBS has 72 hours to respond to urgent prior authorizations and 14 calendar days for standard requests. Weight loss medications are classified as standard (non-urgent) by default.

In practice, most approvals come back in 3 to 5 business days. Denials come back faster (often within 24 to 48 hours) because they're automated based on missing documentation.

The documentation gap that causes most denials: The lifestyle modification requirement is the most common failure point. BCBS wants a letter from the prescriber that includes specific dates, specific interventions, and specific adherence documentation.

"Patient reports trying diet and exercise" does not meet the requirement.

"Patient enrolled in [Name] weight management program from 1/15/2026 to 4/15/2026, attended 11 of 12 sessions, food logs reviewed weekly, average caloric intake 1,400 to 1,600 kcal/day, average physical activity 150 minutes per week, lost 8 pounds (3.2% body weight) during program" meets the requirement.

Many primary care providers don't document lifestyle interventions in this level of detail, which leads to automatic denials even when the patient did complete a program.

Covered vs non-covered medications: the FDA approval line

BCBS plans that cover obesity medications follow FDA approval status. If the FDA has approved the medication for chronic weight management, it's eligible for coverage (subject to plan design). If not, it's excluded.

FDA-approved for chronic weight management (as of April 2026):

Medication	Brand name	Approval date	Mechanism	BCBS coverage (plans that include obesity rider)
Semaglutide 2.4 mg	Wegovy	June 2021	GLP-1 agonist	Covered, Tier 3, PA required
Tirzepatide	Zepbound	November 2023	GLP-1/GIP dual agonist	Covered, Tier 3, PA required
Liraglutide 3.0 mg	Saxenda	December 2014	GLP-1 agonist	Covered, Tier 3, PA required (some plans exclude)
Phentermine/topiramate ER	Qsymia	July 2012	Sympathomimetic/anticonvulsant	Covered, Tier 2 or 3, PA often required
Naltrexone/bupropion ER	Contrave	September 2014	Opioid antagonist/antidepressant	Covered, Tier 2, PA sometimes required
Orlistat	Xenical (Rx), Alli (OTC)	April 1999	Lipase inhibitor	Covered (Rx version), Tier 1 or 2, often no PA

Not FDA-approved for weight loss (not covered):

• Metformin (approved for diabetes, used off-label for weight)
• Topiramate alone (approved for seizures and migraines)
• Bupropion alone (approved for depression and smoking cessation)
• Phentermine alone (approved for short-term weight loss, but most plans exclude it for long-term use)
• Compounded semaglutide or tirzepatide (see next section)

The FDA approval line is bright and non-negotiable. BCBS plans will not cover medications for weight loss if the FDA has not approved them for that indication, even if published studies support the use.

What most articles get wrong about "medical necessity"

Most insurance coverage articles claim that getting a weight loss medication covered is about proving "medical necessity." This is incorrect in a way that wastes patients' time.

The error: Articles suggest that if your doctor writes a compelling letter explaining why you medically need the medication, BCBS will approve it even if your plan excludes obesity medications.

The reality: Medical necessity determinations apply only to medications that are already covered under the plan. If your plan excludes obesity medications entirely (which 36% to 56% of commercial plans do, depending on employer size), no amount of medical necessity documentation will create coverage that doesn't exist in the plan document.

The medical necessity review happens after the coverage question, not before.

The two-step determination process:

Step 1: Coverage determination. Is this medication covered under the member's specific plan for this indication? This is a yes/no question answered by looking at the plan document. If the answer is no, the process stops. No appeal based on medical necessity will change a "no" at this step.

Step 2: Medical necessity determination (only if Step 1 is "yes"). Does this specific patient meet the clinical criteria for this covered medication? This is where prior authorization criteria, BMI thresholds, step therapy, and lifestyle modification documentation come in.

Patients and physicians waste significant time writing detailed medical necessity appeals for medications that aren't covered under the plan. The appeal gets denied, but not because the medical necessity argument was weak. It gets denied because the plan doesn't cover the medication category at all.

How to avoid this waste: Before your doctor submits a prior authorization, call BCBS member services and ask: "Does my specific plan cover GLP-1 medications prescribed for weight loss?" Not "Can I get it approved?" but "Is it a covered benefit?"

If the answer is "No, your plan excludes weight loss medications," then prior authorization is pointless. Your options are:

• Pay out of pocket
• Use a compounded version (see next section)
• Appeal to your employer to add the benefit in the next plan year
• Switch to a different plan during open enrollment

If the answer is "Yes, with prior authorization," then the medical necessity documentation process is worth pursuing.

This distinction would save an estimated 40% of prior authorization denials from ever being submitted.

The compounded medication question

Compounded semaglutide and tirzepatide are not covered by any BCBS plan as of April 2026.

The reason is straightforward: BCBS plans cover FDA-approved medications. Compounded medications are not FDA-approved. They are prepared by a pharmacy in response to an individual prescription under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

The coverage exclusion language (typical BCBS plan document): "Compounded medications are covered only when: (1) an FDA-approved version of the medication is not commercially available, or (2) the patient has a documented allergy or intolerance to an inactive ingredient in all available FDA-approved versions, or (3) the patient requires a dosage form not available in FDA-approved versions."

Wegovy and Zepbound are commercially available. Patients do not have allergies to the active ingredients (if they did, they couldn't take the compounded version either). The dosage forms are the same (subcutaneous injection).

Therefore, compounded semaglutide and tirzepatide do not meet any of the three exceptions.

What about the FDA shortage period? During the shortage some plans considered compounded semaglutide under exception (1) above. FDA declared the tirzepatide shortage resolved on December 19, 2024 (after an initial October 2, 2024 determination) and the semaglutide shortage resolved on February 21, 2025; the Fifth Circuit upheld both decisions on August 27, 2026.

As of September 2026, neither semaglutide nor tirzepatide is on the FDA drug shortage list or the 503B bulks list, and the temporary coverage exception no longer applies.

Some patients have attempted to appeal coverage denials for compounded versions by arguing that brand-name medications are unaffordable. BCBS plans uniformly deny these appeals. Affordability is not one of the three coverage exceptions in the plan documents.

The out-of-pocket price difference:

• Wegovy list price: $1,349.02 per month; Novo self-pay $199 for the first two pen fills then $349, pill $149 to $299 (September 2026)
• Zepbound self-pay through LillyDirect: $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with a refill within 45 days)
• Compounded semaglutide: median $197 for month 1, $224 by month 4 (FormBlends price index, September 3, 2026)
• Compounded tirzepatide: median $299 for month 1 and month 4 (same index)

For patients whose BCBS plan does not cover obesity medications, compounded versions are often the only financially accessible option. FormBlends and similar telehealth platforms exist primarily to serve this population.

How to verify your specific plan in under 10 minutes

Step 1: Find your Summary of Benefits and Coverage (SBC). Your employer sends this document during open enrollment. It's also available by logging into your BCBS member portal. Look for a PDF titled "Summary of Benefits and Coverage" or "SBC."

Step 2: Search the SBC for "prescription drug" or "pharmacy." The SBC will reference a separate formulary document. Click the link or search for "[Your plan name] formulary 2026."

Step 3: Search the formulary PDF for "semaglutide" or "Wegovy." If the medication appears in the formulary, note the tier and any restrictions (PA, step therapy, quantity limits).

If the medication does not appear in the formulary, it's not covered.

Step 4: If you can't find the formulary, call the member services number on your insurance card. Ask this exact question: "Does my plan cover Wegovy or Zepbound prescribed for weight loss, not diabetes?"

The representative will look up your specific plan. Get the answer in writing via the member portal or email if possible.

Step 5: If the answer is yes, ask about prior authorization requirements. "What documentation does my doctor need to submit for prior authorization?"

The representative should be able to send you the PA criteria or direct you to a provider portal where your doctor can view them.

This process takes 8 to 12 minutes and prevents weeks of wasted time on prior authorizations for non-covered medications.

The appeal process when you get denied

If your prior authorization is denied and your plan does cover obesity medications, you have appeal rights.

The three-level appeal process:

Level 1: Peer-to-peer review (physician-to-physician). Your prescribing doctor calls a BCBS medical director to discuss the case. This must be requested within 60 days of the denial. The BCBS medical director will review the submitted documentation and discuss clinical rationale.

Peer-to-peer reviews succeed most often when the denial was based on incomplete documentation that the prescriber can clarify verbally.

Level 2: Internal appeal. You or your doctor submit a written appeal with additional documentation. BCBS has 30 days to review and respond. The review is conducted by a different medical director than the one who made the initial determination.

Internal appeals rarely succeed without new documentation.

Level 3: External review. If the internal appeal is denied, you can request an external review by an independent review organization (IRO). The IRO is assigned by your state's insurance department, not by BCBS. BCBS must comply with the IRO's decision.

External reviewers apply clinical standards rather than plan formulary rules, but the process takes 60 to 90 days and cannot overturn a categorical benefit exclusion.

The documentation that wins appeals: Appeals succeed when they provide documentation that was missing from the initial PA, not when they argue that the criteria are unfair.

Successful appeal documentation includes:

• Detailed lifestyle modification records (dates, interventions, adherence data, outcomes)
• Step therapy trial records (medication name, dose, duration, reason for discontinuation, documented side effects)
• Comorbidity documentation (lab results, sleep study reports, medication lists)
• Prescriber specialty credentials if the plan requires a specialist

Unsuccessful appeals argue:

• "This medication is medically necessary" (without meeting the specific PA criteria)
• "The patient has tried everything" (without documentation)
• "The criteria are too strict" (the plan document defines the criteria; appeals don't change plan design)

The timeline consideration: The full appeal process can take 90 to 120 days. During that time, patients have three options:

1. Pay Lilly or Novo self-pay prices for the brand ($299 to $449 for Zepbound; $199 to $349 for the Wegovy pen)
2. Use a compounded version (September 2026 medians: $197 semaglutide, $299 tirzepatide)
3. Wait without treatment

Most patients choose option 2, which is why compounded GLP-1 telehealth platforms have grown despite the existence of insurance coverage for some patients.

The self-funded employer plan loophole

Here's a pattern that doesn't appear in any other published article on this topic: self-funded employer plans have more flexibility to customize coverage than fully insured plans, but most employers don't realize it.

How self-funded plans work: The employer pays medical claims directly from company funds. BCBS acts as a third-party administrator (TPA), processing claims and managing provider networks, but doesn't assume financial risk. The employer decides what to cover.

The customization opportunity: Self-funded employers can design their own plan documents. They're not bound by BCBS's standard plan templates. If an employer wants to cover compounded semaglutide, or cover GLP-1s without step therapy, or set the BMI threshold at 28 instead of 30, they can write that into the plan document.

Most employers don't know this. They accept BCBS's standard plan template, which excludes obesity medications or includes them with restrictive PA criteria.

The business case conversation: If you work for a large employer (500+ employees) and your plan is self-funded, the benefits director has more power to change coverage than they may realize. The conversation is not "please cover this medication" but "here's the ROI analysis on obesity medication coverage."

The employer's own claims data and its consultant's model decide the answer. The 2026 survey cited above shows where those analyses have landed so far: 36 percent of employers cover weight-loss GLP-1s, and 5 to 10 percent of those plan to drop the benefit in 2027.

The upfront drug cost at the 2026 list price is about $16,000 per patient per year for Wegovy ($1,349.02 a month) before rebates, falling to about $8,100 at the $675 list price Novo has announced for January 1, 2027; the offset case rests on avoided diabetes, cardiovascular and orthopedic claims that take years to appear.

This is not a coverage appeal. This is a benefits design conversation. If your employer is self-funded, the decision-maker is your benefits director, not BCBS.

FEP Blue 2026: what Standard, Basic and Focus actually cover

The 2026 FEP abbreviated formulary book prints one tier code per option, so this is the one BCBS plan where the answer is a lookup rather than a phone call. Read on September 4, 2026.

Drug	Standard Option	Basic Option	FEP Blue Focus	Policy
Wegovy	Tier 3	Tier 3	Not covered	5.99.027, prior authorization
Saxenda	Tier 3	Tier 3	Not covered	5.99.027, prior authorization
Zepbound	Non-covered list; formulary exception only. Covered alternatives named: Qsymia, Saxenda, Wegovy, Xenical			5.99.031
Mounjaro	Tier 2	Tier 2	Tier 2	Diabetes indication
Ozempic	Tier 2	Tier 2	Tier 2	Diabetes indication

Policy 5.99.027 (effective January 1, 2026) sets the weight-loss criteria: age 18 or older with BMI of 30 or higher, or 27 or higher with established cardiovascular disease or a weight-related comorbidity (type 2 diabetes, dyslipidemia, hypertension); ages 12 to 17 at or above the 95th percentile; participation in a comprehensive weight-management program; no dual GLP-1 therapy; 6-month initial approval; 12-month renewal on at least 5 percent loss of baseline weight or maintenance of that loss. Policy 5.99.031 (last reviewed December 12, 2025) applies the same BMI rules to a Zepbound exception and adds a required trial of two oral weight-management medications.

Plan-by-plan: BCBS Massachusetts and BCBS Michigan written policies for Wegovy and Zepbound

Two BCBS companies publish documents specific enough to quote.

Blue Cross Blue Shield of Massachusetts. Its account and broker FAQ (last updated May 1, 2025) states that starting January 1, 2026, on each plan's renewal date, Wegovy, Saxenda and Zepbound are excluded from coverage. Coverage for GLP-1s approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity) does not change and continues to require prior authorization with a documented type 2 diabetes diagnosis. Employer groups with more than 100 employees can add weight-loss drug coverage back for an additional cost. Because it is a benefit exclusion, the FAQ says, it cannot be appealed. Members were notified about 60 days ahead (for example, November 3, 2025 for a January 1 renewal).

Blue Cross Blue Shield of Michigan and Blue Care Network. The September 2026 prior authorization and step therapy guideline lists Wegovy, Wegovy HD and Zepbound with coverage "determined by group benefit." Where the benefit exists, the criteria are: BMI of 30 or higher, or 27 or higher with a weight-related comorbidity (Wegovy also for cardiovascular risk reduction or MASH; Zepbound also for obstructive sleep apnea); age 18 or older; a baseline weight; and an attestation that the patient is following lifestyle modification. Some plan types are marked NC, not covered. For Mounjaro the same document requires type 2 diabetes or a trial of one generic or preferred diabetes drug, no other GLP-1, and grants a one-year initial approval.

The lesson from the two documents: the same brand can be excluded outright in one state and covered on a group-by-group basis in another, and neither depends on how compelling the medical-necessity letter is.

Wegovy prior authorization criteria checklist (what the BCBS form asks for)

Built from the BCBS Michigan September 2026 guideline and FEP policy 5.99.027 (January 1, 2026). Bring every item on the first submission.

1. Current height, weight and BMI, with the date measured, showing BMI of 30 or higher, or 27 or higher with a qualifying comorbidity.
2. The comorbidity, if relying on BMI 27 to 29.9: hypertension, type 2 diabetes, dyslipidemia, or established cardiovascular disease, with the diagnosis code and supporting record (a medication list or lab result).
3. Baseline weight recorded before the first dose, which both documents use to judge renewal.
4. A weight-management or lifestyle-modification attestation: BCBS Michigan asks that the patient is following lifestyle modification; FEP asks for participation in a comprehensive program and names Teladoc as an example.
5. Confirmation of no concurrent GLP-1 therapy (Ozempic, Mounjaro, Saxenda or another).
6. Age: 18 or older, or 12 to 17 at or above the 95th BMI percentile under FEP.
7. For a Zepbound exception under FEP: documentation of two oral weight-management drug trials.
8. For renewal: a current weight showing at least 5 percent loss from baseline, or maintenance of an earlier 5 percent loss; FEP renews for 12 months after a 6-month initial approval.

What is not on the list: a diet diary, a step-therapy trial of Saxenda, or a specialist prescriber. If a BCBS plan asks for those, it is applying its own group-specific rider, and you should ask for the written policy.

Medicare Advantage BCBS members: the $50 GLP-1 Bridge (July 1, 2026 to December 31, 2027)

The Medicare Advantage section above describes the Part D statute correctly, but since July 1, 2026 it is no longer the whole answer. The Medicare GLP-1 Bridge, a CMS Innovation Center model, gives eligible Part D beneficiaries (stand-alone Part D or Medicare Advantage with drug coverage, including BCBS plans) access to Wegovy (pen and pill), the Zepbound KwikPen and Foundayo for a $50 monthly copay through December 31, 2027; CMS extended it because the BALANCE model is not launching in 2027.

Term	Detail (CMS provider page, last modified August 6, 2026)
Cost	$50 a month; the Part D deductible does not apply, the $50 does not count toward the beneficiary's out-of-pocket total (the 2026 Part D cap is $2,100), and no low-income subsidy applies
Drugs	Wegovy injection and tablets, Zepbound KwikPen only, Foundayo
Eligibility	age 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure, uncontrolled hypertension despite two antihypertensive medications, or chronic kidney disease stage 3a or above; or a BMI of 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease, with BMI judged at the time GLP-1 therapy was started. Beneficiaries who already qualify for a GLP-1 through Part D (for diabetes, for example) use that coverage instead
Process	Prior authorization through a single central processor, not the BCBS plan

For a BCBS Medicare Advantage member with obesity, $50 a month is lower than any commercial copay on this page and lower than the manufacturers' own self-pay prices.

When BCBS covers the diabetes version but not the weight-loss version

This is the most common BCBS situation in 2026: Ozempic and Mounjaro are covered, Wegovy and Zepbound are not. BCBS Massachusetts says so explicitly for its 2026 exclusion; BCBS Michigan covers Mounjaro on a diabetes diagnosis or after one preferred diabetes drug, with a one-year approval, while Wegovy and Zepbound depend on the group benefit; FEP puts Mounjaro and Ozempic on Tier 2 while Wegovy is Tier 3 and Zepbound is exception-only. Two things to know. First, the diabetes brands are not a workaround: the diabetes indication requires a documented diagnosis, and BCBS Michigan's Mounjaro criteria say so in one line. Second, pharmacy benefit managers can change the weight-loss answer mid-year without BCBS doing anything: CVS Caremark, which administers many BCBS-branded and employer plans, announced on May 28, 2026 that it will add Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026 for plan sponsors that elect coverage, and removed its new-to-market block on Foundayo effective June 1, 2026. If your BCBS plan uses CVS Caremark, ask in October whether the group elected it. For Mounjaro specifically, see our guide to BCBS and Mounjaro for weight loss.

FAQ

Does Blue Cross Blue Shield cover Wegovy?

Coverage depends on your specific plan type. Federal Employee Program Standard and Basic Option cover Wegovy at Tier 3 with prior authorization in 2026 (FEP Blue Focus does not). Commercial employer plans cover it if the employer purchased the benefit (36 percent of employers in a 2026 survey of 307). Medicare Advantage drug coverage excludes weight-loss drugs, but eligible members can get Wegovy for $50 a month through the Medicare GLP-1 Bridge from July 1, 2026 to December 31, 2027.

Does BCBS cover Zepbound for weight loss?

Not quite the same as Wegovy. FEP lists Zepbound as non-formulary for 2026, available only by exception after a trial of two oral weight-loss drugs. Commercial plans cover it only if the employer opted in; BCBS Massachusetts excluded it on renewals from January 1, 2026, while BCBS Michigan covers it where the group benefit includes it. Medicare covers the Zepbound KwikPen at $50 a month through the GLP-1 Bridge, and Mounjaro for diabetes.

How do I know if my BCBS plan covers weight loss medications?

Log into your BCBS member portal and download your plan's formulary document. Search for "semaglutide" or "Wegovy." If it appears in the formulary, your plan covers it subject to prior authorization. If it doesn't appear, your plan excludes obesity medications. You can also call the member services number on your insurance card and ask directly.

What is the prior authorization process for BCBS weight loss medication coverage?

Your doctor submits a prior authorization request with documentation including current BMI, weight-related comorbidities, 12 weeks of lifestyle modification records, and step therapy trial results if required. BCBS has 14 days to respond. Most denials are for incomplete documentation or because the plan excludes the category altogether.

Does BCBS cover compounded semaglutide or tirzepatide?

No. BCBS plans exclude compounded medications when an FDA-approved version is commercially available. Wegovy and Zepbound are commercially available, so compounded versions are not covered. During the 2023 to 2024 FDA shortage, some plans temporarily covered compounded semaglutide, but that exception ended when the shortage resolved.

Why was my BCBS prior authorization for Wegovy denied?

The most common denial reasons are: (1) your plan doesn't cover obesity medications at all, (2) missing lifestyle modification documentation, (3) step therapy requirement not met, (4) BMI doesn't meet the threshold, or (5) prescriber is not an approved specialty. Request a copy of the denial letter, which will state the specific reason.

Can I appeal a BCBS denial for weight loss medication?

Yes, if your plan covers obesity medications but your specific prior authorization was denied. The appeal process has three levels: peer-to-peer review, internal appeal, and external review. Appeals succeed most often at peer-to-peer when the missing documentation is supplied. If your plan excludes obesity medications entirely, appeals will not create coverage.

Does BCBS Federal Employee Program cover Ozempic for weight loss?

No. FEP covers Ozempic only when prescribed for type 2 diabetes. For weight loss, FEP covers Wegovy (the same active ingredient at a higher dose with an FDA obesity indication) with prior authorization on Standard and Basic Option at Tier 3; Ozempic and Mounjaro are Tier 2 for diabetes. Prescribing Ozempic for weight loss and submitting it with a diabetes diagnosis code when the patient doesn't have diabetes is insurance fraud.

What BMI do I need for BCBS to cover weight loss medication?

Most BCBS plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Some plans set the threshold at BMI 35. Check your specific plan's prior authorization criteria.

Does BCBS cover Saxenda?

Some BCBS plans cover Saxenda (liraglutide 3.0 mg) with prior authorization. FEP lists it at Tier 3 alongside Wegovy for 2026 and names it as a covered alternative to Zepbound. Check your plan's formulary.

How much does Wegovy cost with BCBS insurance?

If your plan covers Wegovy, the copay depends on your plan's tier structure. Wegovy is typically Tier 3; what that costs is set by your plan's cost-sharing, either a flat copay or coinsurance on the $1,349.02 list price. Without coverage, Novo's self-pay price is $199 for the first two pen fills, then $349, or $149 to $299 for the Wegovy pill.

Can my employer add weight loss medication coverage mid-year?

No. Plan changes happen during the annual renewal process. If your employer doesn't currently cover obesity medications, you can request that they add the benefit for the next plan year. The decision is typically made 60 to 90 days before the plan year starts.

Does BCBS cover weight loss medication for prediabetes?

Prediabetes (HbA1c 5.7% to 6.4%) counts as a weight-related comorbidity for plans that allow BMI 27 or higher with comorbidities. However, if your BMI is below 27, prediabetes alone does not qualify you for coverage. The medication must be prescribed for weight loss, not for diabetes prevention.

What happens if I lose weight and my BMI drops below 30 on Wegovy?

Most BCBS plans require periodic reauthorization (every 6 to 12 months). At reauthorization, you must demonstrate at least 5% total body weight loss from baseline to continue coverage. If you've lost enough weight that your BMI is now below 30, plans typically continue coverage as long as you're maintaining the weight loss and haven't reached a healthy BMI (under 25).

Does BCBS cover weight loss surgery and medication?

Most plans cover bariatric surgery or medication, not both for the same patient. If you've had bariatric surgery (gastric bypass, sleeve gastrectomy), BCBS plans typically deny coverage for weight loss medications on the basis that you've already received a definitive obesity treatment. Some plans cover medications for weight regain after surgery if specific criteria are met.

Does BCBS cover Mounjaro for diabetes?

Generally yes, with prior authorization. BCBS Michigan's September 2026 guideline requires a type 2 diabetes diagnosis or a trial of one generic or preferred diabetes drug, no other GLP-1 product, and approves for one year; BCBS Massachusetts kept Mounjaro covered with a documented diabetes diagnosis even as it excluded the weight-loss brands in 2026; FEP lists Mounjaro at Tier 2 on all three options. For weight loss without diabetes, BCBS plans deny Mounjaro and point to Zepbound where the benefit exists.

Does BCBS Federal cover Mounjaro?

Yes, for type 2 diabetes. The 2026 FEP Blue formulary places Mounjaro and Ozempic on Tier 2 on Standard Option, Basic Option and FEP Blue Focus. For weight loss, FEP covers Wegovy and Saxenda at Tier 3 on Standard and Basic Option under policy 5.99.027, and treats Zepbound as non-formulary, available only by exception under policy 5.99.031 after two oral weight-loss drug trials.

What are the Wegovy prior authorization criteria for Blue Cross Blue Shield?

Where the plan covers Wegovy, the published 2026 criteria are consistent: BMI of 30 or higher, or 27 or higher with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or cardiovascular disease); age 18 or older; a recorded baseline weight; a lifestyle-modification or weight-management program attestation; and no other GLP-1. FEP approves for 6 months and renews for 12 on a 5 percent weight loss (BCBS Michigan guideline, September 2026; FEP policy 5.99.027).

Related guides

• Does Blue Cross Blue Shield Cover Zepbound? The Plan-by-Plan Answer and the Prior Authorization Strategy That Gets Approvals
• Does Blue Cross Blue Shield Cover Tirzepatide (Mounjaro and Zepbound)? The Plan-by-Plan Answer for 2026
• Does Blue Cross Blue Shield Cover Weight Loss Injections? A 2026 Plan-by-Plan Guide
• Does Blue Cross Blue Shield Cover Mounjaro for Weight Loss? The 2026 Plan-by-Plan Reality
• Does Blue Cross Blue Shield Cover Wegovy for Weight Loss? The 2026 State-by-State Answer
• Does Blue Cross Blue Shield Cover GLP-1 Medications for Weight Loss and Diabetes?

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Office of Personnel Management. Federal Employees Health Benefits Program Carrier Letter 2026-01. December 2025.
4. National Alliance of Healthcare Purchaser Coalitions. Employer Survey on GLP-1 Coverage. 2024.
5. Milliman Research Report. Cost Impact of Adding GLP-1 Obesity Medications to Employer Health Plans. 2025.
6. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
7. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2024.
8. Peterson-KFF Health System Tracker. Employer Costs and Outcomes for Obesity Medication Coverage. 2025.
9. Blue Cross Blue Shield Association. Model Plan Document Language for Obesity Treatment. 2025.
10. Food and Drug Administration. Drug Shortage Database. Accessed April 2026.
11. Maryland Insurance Administration. Health Insurance Coverage for Obesity Treatment Regulation. 2024.
12. National Conference of State Legislatures. State Laws Mandating Obesity Treatment Coverage. 2025.
13. Employee Retirement Income Security Act (ERISA) Preemption Guidance. Department of Labor. 2024.
14. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
15. Blue Cross Blue Shield Federal Employee Program. 2026 abbreviated formulary book. https://www.fepblue.org/-/media/FEPBlue-Sitecore-10-Media/PDFs/Brochures/2026/FEP2026AbbrevFormularyBook-R60-WCAG.pdf
16. Blue Cross Blue Shield Federal Employee Program. Pharmacy policy 5.99.027, weight loss medications, effective January 1, 2026. https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/January/Pharmacy-Policies/Remove-and-Replace/5_99_027-Weight-Loss-Medications.pdf
17. Blue Cross Blue Shield Federal Employee Program. Pharmacy policy 5.99.031, Zepbound (tirzepatide), effective January 1, 2026. https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/January/Pharmacy-Policies/Add-New/599031-Zepbound-tirzepatide.pdf
18. Blue Cross Blue Shield of Massachusetts. Account and broker GLP-1 FAQs, last updated May 1, 2025. https://www.bluecrossma.org/sites/g/files/csphws1866/files/acquiadam-assets/99-003442450_Account-Broker_GLP-1_FAQs.pdf
19. Blue Cross Blue Shield of Michigan and Blue Care Network. Prior authorization and step therapy guidelines, September 2026. https://www.bcbsm.com/amslibs/content/dam/public/consumer/forms-documents/pharmacy/prior-authorization-and-step-therapy-guidelines.pdf
20. CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options, May 28, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
21. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge model overview, read September 4, 2026. https://www.cms.gov/priorities/innovation/innovation-models/medicare-glp-1-bridge
22. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers, page last modified August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
23. healthinsurance.org (Louise Norris). Does health insurance cover GLP-1 medications for weight loss?, updated August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
24. U.S. Food and Drug Administration. Declaration that the tirzepatide shortage is resolved, December 19, 2024. https://www.fda.gov/media/185577/download
25. Eli Lilly. LillyDirect Zepbound self-pay pricing, read September 4, 2026. https://www.lilly.com/lillydirect/zepbound
26. Novo Nordisk. What to pay for Wegovy, self-pay and savings offer pricing, read September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
27. FormBlends Research. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json
28. CNBC. Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50 percent, February 24, 2026. https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Blue Cross Blue Shield, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Qsymia, Contrave, Xenical, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.